Price Chart

Profile

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
URL https://www.crisprtx.com
Investor Relations URL http://ir.crisprtx.com/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 06, 2024 (est.)
Last Earnings Release Aug. 05, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
URL https://www.crisprtx.com
Investor Relations URL http://ir.crisprtx.com/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 06, 2024 (est.)
Last Earnings Release Aug. 05, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A